THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is the one-stop reference you need, whether you’re making investment decisions, pitching to potential partners, or estimating the value of an R&D program.
- Vetted benchmarks for key drivers of income, expenses, and valuation.
- Proprietary analyses from Pharmagellan’s experienced consulting team.
- More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.
"Deserves a spot on the bookshelf of every biotech CFO."
- Bruce Booth, Partner, Atlas Venture
Free sample chapter: Projecting Market Share for R&D-Stage Biotechs
Read the table of contents and get more details here